CVS Health: Strategic Board Enhancements and Undervaluation Drive Buy Rating
Leerink Adjusts Price Target on CVS Health to $57 From $63, Maintains Market Perform Rating
Wells Fargo Upgrades CVS Health to Overweight From Equalweight, Adjusts Price Target to $66 From $60
RBC Capital lowered CVS Health's target price to $58.
CVS Health Is Maintained at Outperform by RBC Capital
CVS Health Analyst Ratings
RBC Capital Maintains CVS Health(CVS.US) With Buy Rating, Cuts Target Price to $58
RBC Capital Reaffirms Their Buy Rating on CVS Health (CVS)
J.P. Morgan Maintains CVS Health(CVS.US) With Buy Rating, Cuts Target Price to $80
J.P. Morgan Reaffirms Their Buy Rating on CVS Health (CVS)
TD Cowen Maintains CVS Health(CVS.US) With Buy Rating, Cuts Target Price to $73
TD Cowen Cuts Price Target on CVS Health to $73 From $85
CVS Health: Buy Rating With Projected EPS Growth and Strategic Optimism Amid Retail Challenges
A Quick Look at Today's Ratings for CVS Health(CVS.US), With a Forecast Between $62 to $85
Barclays lowers the target price of cvs health to $71
CVS Health's Performance Amid Election Impact and HCB Uncertainties: Hold Rating Maintained
CVS Health Is Maintained at Neutral by UBS
CVS Health Analyst Ratings
Barclays Maintains Overweight on CVS Health, Lowers Price Target to $71
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cross Country Healthcare (CCRN), CVS Health (CVS) and Privia Health Group (PRVA)